Oxidative stress in Systemic Sclerosis
- PMID: 10448906
Oxidative stress in Systemic Sclerosis
Abstract
In 63 patients affected by Systemic Sclerosis (SSc) (limited subset: 40; diffuse subset: 23; early: 30; advanced: 33) the peroxidation product diene-conjugates (DC) and antibodies against oxidised low density lipoproteins (Ab oxLDL) were tested in serum by a spectrophotometer (absorbance 234 mn) and by a standard ELISA respectively. The data were compared with those obtained by 21 healthy subjects. DC was significantly higher in patients (73.3 +/- 37.2 microM/l; p < 0.0001) than in controls (48.4 +/- 16.7) as well as in the limited (80 +/- 48.8; p < 0.05) than in the diffuse subset (64.5 +/- 36.4); and in early (84.1 +/- 31.4; p < 0.05) than in advanced stage of the disease (67.9 +/- 42.5). The levels of Ab oxLDL were significantly higher in SSc patients (309.5 +/- 367.2 mU/ml; p < 0.0001) in all its subsets (limited: 351.9 +/- 351.1, p < 0.0001; diffuse: 207.7 +/- 316.1, p < 0.05; early: 428.9 +/- 417.1, p < 0.001; advanced: 302.7 +/- 89.9, p < 0.0001) than in controls (89.3 +/- 29.1). These antibodies levels were higher in limited subset than in diffuse (p < 0.05) and in early SSc than in advanced SSc (p < 0.05). The highest values of parameters of oxidative stress are found in the early stages, when the episodes of reperfusion after ischemic episodes (Raynaud's phenomenon) are very frequent. Moreover, the damage is higher in the early stages of SSc, with intact microvessels, than in late stages, when microvessels are very reduced in number, destroyed by the worsening of the disease. These data show that the respiratory burst deduced by the lipoperoxidation is higher in SSc than in controls, and may be an important pathogenetic factors involved in tissue changes in SSc.
Similar articles
-
Evidence for immune activation against oxidized lipoproteins in inactive phases of juvenile chronic arthritis.J Rheumatol. 2001 Jan;28(1):198-203. J Rheumatol. 2001. PMID: 11196525
-
Antibodies against oxidized low-density lipoproteins in systemic sclerosis.Rheumatology (Oxford). 2001 Apr;40(4):401-5. doi: 10.1093/rheumatology/40.4.401. Rheumatology (Oxford). 2001. PMID: 11312377
-
OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement.Ann N Y Acad Sci. 2005 Jun;1051:313-22. doi: 10.1196/annals.1361.073. Ann N Y Acad Sci. 2005. PMID: 16126973
-
Oxidative stress in the pathogenesis of systemic scleroderma: An overview.J Cell Mol Med. 2018 Jul;22(7):3308-3314. doi: 10.1111/jcmm.13630. Epub 2018 Apr 17. J Cell Mol Med. 2018. PMID: 29664231 Free PMC article. Review.
-
Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis.Toxicology. 2000 Nov 30;155(1-3):1-15. doi: 10.1016/s0300-483x(00)00272-9. Toxicology. 2000. PMID: 11154792 Review.
Cited by
-
Lipid peroxidation and trace elements in systemic sclerosis.Clin Rheumatol. 2006 May;25(3):320-4. doi: 10.1007/s10067-005-0013-4. Epub 2005 Oct 25. Clin Rheumatol. 2006. PMID: 16249831
-
Cardiorheumatology: cardiac involvement in systemic rheumatic disease.Nat Rev Cardiol. 2015 Mar;12(3):168-76. doi: 10.1038/nrcardio.2014.206. Epub 2014 Dec 23. Nat Rev Cardiol. 2015. PMID: 25533796 Free PMC article. Review.
-
Skin autofluorescence, as marker of accumulation of advanced glycation endproducts and of cumulative metabolic stress, is not increased in patients with systemic sclerosis.Int J Rheumatol. 2011;2011:417813. doi: 10.1155/2011/417813. Epub 2011 Sep 29. Int J Rheumatol. 2011. PMID: 21977038 Free PMC article.
-
The Potential of Twendee X® as a Safe Antioxidant Treatment for Systemic Sclerosis.Int J Mol Sci. 2024 Mar 6;25(5):3064. doi: 10.3390/ijms25053064. Int J Mol Sci. 2024. PMID: 38474309 Free PMC article.
-
Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis.Clin Rheumatol. 2007 Sep;26(9):1517-21. doi: 10.1007/s10067-007-0613-2. Epub 2007 Mar 31. Clin Rheumatol. 2007. PMID: 17401513 Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials